Please assess the completion status of the following clinical trial:

Trial Title: Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age~* Have end stage renal disease (ESRD) and is receiving a kidney transplant from a living donor to whom he/she has a baseline anti-blood group titer \>1:32~* Be vaccinated against N. meningitides (quadrivalent vaccine), H. Flu, and pneumococcal disease at least two weeks prior to beginning desensitization.~Exclusion Criteria:~* Has an unstable cardiovascular condition~* Has had a previous splenectomy~* Has any active bacterial or other infection~* Has a known or suspected hereditary complement deficiency~* Has known hypersensitivity to the treatment drug or any of its excipients~* Has history of illicit drug use or alcohol abuse within the previous year~* Has history of meningococcal disease~* Has any medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eculizumab (Type: EXPERIMENTAL): Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).